Pfizer

Nieuws

Reuters - 7 uur geleden

What to Watch in the Week Ahead and on Monday, July 29

What to Watch in the Week Ahead and on Monday, July 29 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY McDonald's is expected to post a smaller growth in second-quarter revenue as customers cut back on dining out amid persistent inflation.

Reuters - 12 uur geleden

Pfizer Inc <PFE.N> expected to post earnings of 46 cents a share - Earnings Preview

Pfizer Inc expected to post earnings of 46 cents a share - Earnings Preview Pfizer Inc PFE.N , PFE is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The New York City-based company is expected to report a 2.3% increase in revenue to $13.024 billion from $12.73 billion a year ago, according to the mean estimate from 15 analysts, based on LSEG data.

Reuters - 2 dagen geleden

UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain

UPDATE 1-UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain Adds details in paragraphs 2 & 3 July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant for use in infants, children and adults. The Medicines and Healthcare products Regulatory Agency (MHRA) said it has approved four forms of the adapted Comirnaty JN.1 vaccine after reviewing its safet

Reuters - 2 dagen geleden

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults. Reporting by Unnamalai L in Bengaluru; Editi

Reuters - 2 dagen geleden

UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant

BRIEF-UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant July 24 (Reuters) - UK's MHRA: UK'S MHRA: APPROVED AN ADAPTED PFIZER/BIONTECH COVID-19 VACCINE (COMIRNATY) THAT TARGETS THE JN.1 COVID-19 SUBVARIANT UK'S MHRA: FOUR FORMS OF THIS ADAPTED COMIRNATY JN.1 VACCINE HAVE BEEN APPROVE

Reuters - 3 dagen geleden

Sangamo rises on bleeding disorder gene therapy trial data

BUZZ-Sangamo rises on bleeding disorder gene therapy trial data ** Shares of gene therapy developer Sangamo Therapeutics SGMO.O rise ~73.6% to 67 cents premarket ** SGMO says co and partner Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study *

Reuters - 3 dagen geleden

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.

Reuters - 3 dagen geleden

Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate

BRIEF-Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate July 24 (Reuters) - Pfizer Inc PFE.N : PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF HEMOPHILIA A GENE THERAPY CANDIDATE PFIZER: ANALYSES OF FULL PHASE 3 DATASET FROM AFFINE STUDY ONGOING PFIZER: IN AFFINE STUDY, GIROCTOCOGENE

Reuters - 3 dagen geleden

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial July 24 (Reuters) - Pfizer PFE.N said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.

Reuters - 4 dagen geleden

Merck's RSV shot helps protect infants in mid-to-late stage study

UPDATE 3-Merck's RSV shot helps protect infants in mid-to-late stage study Adds analyst comment in paragraph 3 By Vaibhav Sadhamta July 23 (Reuters) - Merck's MRK.N antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on Tuesday.

Reuters - 4 dagen geleden

GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy

BRIEF-GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy July 23 (Reuters) - GSK plc GSK.L : GSK: VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY GSK: VIV'S FINDINGS SHOW MATERNAL AND PREGNANCY OUTCOMES WITH APRETUDE EXPOSURE WERE COMPARABLE TO THOSE WITH NO CABOTEGRAVIR EXPOSURE Source

Reuters - 1 week geleden

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say Adds share reaction in paragraph 4 By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.6 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.

Reuters - 1 week geleden

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.3 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.

Reuters - 1 week geleden

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.

Reuters - 1 week geleden

Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion

BRIEF-Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion July 17 (Reuters) - Valneva SE VLS.PA : PHASE 3 VALOR LYME DISEASE TRIAL: VALNEVA AND PFIZER ANNOUNCE PRIMARY VACCINATION SERIES COMPLETION VALNEVA - PRIMARY VACCINATION SERIES TO BE FOLLOWED BY A BOOSTER APPROXIMATELY ONE YEAR AFTER COMPLETION VALNEVA SE: PFIZER PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO U.S.

Reuters - 1 week geleden

Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17)

CORRECTED-Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17) Removes reference in July 17 story to Pfizer's pediatric version of Bicillin-L-A in paragraph 3 July 17 (Reuters) - Mark Cuban's Cost Plus Drug Company said on Wednesday that it is working with the U.S. Food and Drug Administration to import and distribute penicillin in the country temporarily.

Reuters - 1 week geleden

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates with latest details on Pfizer, Roche and Carmot Therapeutics July 17 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

Reuters - 1 week geleden

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason JERUSALEM, July 17 (Reuters) - Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round. Nvidia NVDA.O , Pfizer PFE.N , Thermo Fisher TMO.N and venture capital investor OurCrowd participated in the round, CytoReason said.

Reuters - 1 week geleden

EU court criticises Commission over handling of COVID vaccine contracts

UPDATE 3-EU court criticises Commission over handling of COVID vaccine contracts Adds more reaction from Commission in paragraphs 8-10 By Foo Yun Chee and Bart H. Meijer BRUSSELS, July 17 (Reuters) - Europe's second-highest court on Wednesday criticised the European Commission for a lack of transparency over COVID-19 vaccine contracts four years ago, a day before a key vote on Commission head Ursula von der Leyen's bid for a second term.

Reuters - 1 week geleden

Roche touts early trial success of second obesity drug candidate

UPDATE 4-Roche touts early trial success of second obesity drug candidate Adds executive comment from paragraph 11 By Ludwig Burger and Paolo Laudani July 17 (Reuters) - Roche ROG.S said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs.

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Pfizer

Nieuws

Voorwaarden

Populaire activa

Live chat van XM